An interventional study of Transbronchial Cryobiopsy,TBLC and Transbronchial Lung Biopsy,TBLB in Pulmonary Fibrosis and Transbronchial Cryobiopsy, sponsored by China-Japan Friendship Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-10.
Sponsored by China-Japan Friendship Hospital · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Pulmonary Fibrosis with a site in China — 14 open to participants now, 18 under way, 4 of them phase 3. Pulmonary Fibrosis · China.
Among the 40 studies in Pulmonary Fibrosis with a site in China, this one is the 18th largest by planned enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2024, is one of 4 with no phase, reaches primary completion later than 5 of the 17 other live ones, and was the 29th registered.
342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.
Browse Pulmonary Fibrosis studies →14 of the 40 studies in Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:
Peking Union Medical College Hospital · Sites in China
Ages 18–85 · Healthy volunteers
Ming Zhong · Sites in China
Ages 18–89
Zuojun Xu · Sites in China
ChromX Health · Sites in China
Ages 18–100 · Healthy volunteers
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 10 · Phase 3 8
First in 2007; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 59 across 212 interventional studies indexed under Pulmonary Fibrosis.
Median enrollment 146 across the 30 interventional studies, 200 across the 10 observational. Of the 18 that completed or were terminated, 9 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 40 have an industry lead sponsor. The 10 most frequent:
China-Japan Friendship Hospital is the lead sponsor of 179 studies on the registry; 112 are open to participants now.
China-Japan Friendship Hospital has 2 studies filed under Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Pulmonary Fibrosis with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06125327Phase 3Guangzhou JOYO Pharma Co., LtdSC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) | 2026-12-31 |
| NCT05139719Sunshine Lake Pharma Co., Ltd.A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients | 2026-12 |
| NCT06528418ChromX HealthIdentification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath | 2026-12-30 |
| NCT07396467The First Affiliated Hospital with Nanjing Medical UniversityClinical Outcomes and Immunotherapy in Lung Cancer With Pulmonary Fibrosis | 2026-12-31 |
| NCT07464132Peking Union Medical College HospitalApplication of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases | 2027-02-17 |
Add all 5 to your calendar (.ics) → With an account.
Among the 40 studies in Pulmonary Fibrosis with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical study is to learn about the diagnostic effectiveness, safety, and influencing factors of transbronchial cryobiopsy(TBLC)in progressive pulmonary fibrosis. The main question it aims to answer are: • Determine the prognosis, health economics, and therapeutic strategy changes of patients with TBLC retrograde malleable pulmonary fibrosis. Participants will be randomly divided into two groups, and received TBLB or TBLC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with PPF, ≥18 years of age, unclassified ILD, HRCT ≤3 months, forced vital capacity (FVC)≥50% predicted value, pulmonary carbon monoxide diffusion (DLCO)≥35% predicted value, echocardiography ≤12 months, estimated pulmonary systolic blood pressure ≤40 mmHg, (BMI)≤35 kg/m2.
Exclusion Criteria:
Patients with counts below 50,000×109/L or of prothrombin time (INR) above 1.5 are not eligible for TBLC
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Transbronchial lung cryobiopsy (TBLC) has been increasingly utilised to diagnose diffuse parenchymal lung diseases
Procedure: Transbronchial Cryobiopsy,TBLC
Transbronchial lung biopsy (TBLB) is a relatively safe technique routinely employed by pulmonologists for the diagnosis of diffuse parenchymal lung disease
Procedure: Transbronchial Lung Biopsy,TBLB
Transbronchial lung cryobiopsy (TBLC) is a novel technique that has proved its diagnostic value in various diffuse parenchymal lung diseases
Transbronchial lung biopsy (TBLB) is a relatively safe technique routinely employed by pulmonologists for the diagnosis of diffuse parenchymal lung disease
the diagnostic performance of transbronchial cryobiopsy(TBLC)
the sensitivity and specificity of transbronchial cryobiopsy(TBLC)in suspected progressive pulmonary fibrosis
Time frame: 1 month after transbronchial cryobiopsy
the safety of transbronchial cryobiopsy(TBLC)
The occurence of short-term procedure-related complications, including Bleeding, pneumothorax, death, etc
Time frame: 7 days and 1 month after transbronchial cryobiopsy
Started Feb 2024 (actual). Primary completion is estimated for Jun 2026, 28 months after the start.
Of 41 interventional studies with no phase under Pulmonary Fibrosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 81. This study's planned 28 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China-Japan Friendship Hospital →